Por: ABC7 Health June 06, 2023
CHICAGO -- Hundreds of people using the test company Grail were wrongly told they might have cancer, the company said in a statement Monday.Grail said a software glitch related to their telemedicine vendor, PWNHealth, caused them to send letters to about 400 patients saying they might have cancer when they do not. Grail said the glitch affected customers who had ordered their Galleri test.Grail said it was notified by PWNHealth about the issue... + full article
Los Angeles Times USA Business June 03, 2023
Cancer screening outfit Grail said Friday that a software glitch at a third-party telemedicine vendor led to erroneous letters being sent to about 400 people warning that they may have developed cancer. Grail is owned by San Diego’s Illumina, the leader in DNA sequencing... + más
F.T.C. Orders Gene-Sequencing Company Illumina to Divest Acquisition | The New York Times
FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business
Ars Technica USA Science June 03, 2023
Navigate Filter by topic Settings Front page layout Site theme - Jun 3, 2023 11:20 am UTC / Grail is a subsidiary of Illumina, the world’s biggest gene sequencing company.Grail More than 400 patients who signed up to take a pioneering oncology detection test developed by US... + más
Software glitch leads to 400 Grail patients getting bogus letters saying they might have cancer | Los Angeles Times
The New York Times USA Business April 03, 2023
The Federal Trade Commission on Monday ordered Illumina, the leading maker of gene-sequencing machines, to divest Grail, a cancer-test developer.The move by the F.T.C. is the latest development in a case seen by antitrust experts as a to stop big companies from buying fledgling... + más
Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC
Fox Business USA Business April 03, 2023
Check out whats clicking on FoxBusiness.com The on Monday ordered life sciences company Illumina to unwind its $7.1 billion acquisition of cancer detection test developer Grail Inc., citing antitrust concerns. The commission voted unanimously in a 4-0 decision to force Illumina... + más
CNBC USA Health March 24, 2023
In this articleCarl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan CNBCCarl Icahn on Friday alleged that 's directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of cancer... + más
Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC
CNBC USA Health March 21, 2023
In this articleCarl IcahnAdam Jeffery CNBC Biotech company pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees do not add value. The San Diego-based DNA... + más
Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC
CNBC USA Business March 18, 2023
Business: develops, manufactures and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and Grail. Grail, which was acquired in , is a health-care company focused on early detection of... + más
About iurex | Privacy Policy | Disclaimer |